Buchang Pharmaceutical announced that its controlling subsidiary, Luzhou Buchang, recently signed a technical service contract with WuXi AppTec to conduct pharmacokinetic and toxicology testing projects. The total contract value is RMB 10.8 million, including 6% tax, and will be paid in installments as agreed in the contract. This move will help expand the company's drug R&D capabilities and scope, reduce time and costs associated with clinical trials, and ensure the smooth progress of the project.